Liu Hui, M.D.,Ph.D.

Department: Hematology

Medical School: Zhejiang University School of Medicine, China

Academic Rank: Associate Chief Physician


Appointment

Clinical / Research Interests

Standardized diagnosis and treatment of hematological malignancies, especially malignant lymphoma

Professional Highlights

Zhejiang Scientific and Technological Progress Award, Second Prize 

Professional Appointments

Young Member, Chinese Society of Hematology, Chinese Medical Association

Young Member, Chinese Society of Hematology, Zhejiang Association of Integrated Medicine

Young Member, Hematology Branch, Zhejiang Society of Immunology

Member, Hematology Branch, Zhejiang Society of Immunology


Education Experience

Research Summary

Publications

Yang C, Huang X, Liu H, et al. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. Oncotarget. 2017; 8(24): 39185-39197.

You LS, Liu H, Huang J, et al. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. Oncotarget. 2017; 8(5): 7777-7790.

Liu H, Zhu L, Sun CH, et al. Clinical significance and prognostic value of STAT3 expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. International Journal of Clinical and Experimental Medicine. 2016; 9(6): 9356-9364.


Current Program

Research on Regulating the Immune Checkpoint Signaling Pathway to Enhance the Anti-B-Cell Lymphoma Effect of CAR-T. Funding Resource: General Program of  Zhejiang Natural Science Foundation 

Find People

Search by Family Name

Find A Department

Search by Departments